<DOC>
	<DOC>NCT02757079</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy on sleep latency with electronic sleep diaries and the safety of NPC-15.</brief_summary>
	<brief_title>Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders</brief_title>
	<detailed_description>This study will be a multicenter and open label trial. The trial has three phases; the screening phase, treatment phase and post-treatment phase. The screening phase comprises a screening visit where subject's initial eligibility will be evaluated. During open label treatment phase, all patients will be administered NPC-15 1 mg, 2 mg or 4 mg on the basis of their doctors' judgements.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Neurodevelopmental Disorders</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>Female or male patients aged 6 to 15 years. Patients with "neurodevelopmental disorder" diagnosed by using DSM5. Patients with average of daily sleep latency persisted over 30 min and the condition is continuous over 3 months Patients who are outpatient, not hospitalized patient. Signed informed consent obtained from rearer(s)/parent(s)/guardian(s) of the patient, or signed IC or informed assent obtained from the patient themselves. Patients with at least severity in either Conceptual area, or Social area, or Practical area of intellectual disability have judged more than " the most severe" by using DSM5. Patients who took melatonin (including supplement) in history. Patients who had taken Ramelteon within 4 weeks before clinical study starts.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Melatonin</keyword>
	<keyword>NPC-15</keyword>
	<keyword>Sleep disorders</keyword>
	<keyword>Neurodevelopmental disorder</keyword>
	<keyword>Sleep latency</keyword>
	<keyword>DSM-5</keyword>
</DOC>